Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Cumberland Pharmaceuticals Sues Perrigo and InnoPharma

Cumberland Pharmaceuticals, the maker of prescription drugs for emergency medicine, accused generic-drug makers Perrigo Co. and InnoPharma Inc. of infringing a patent for Acetadote, used to treat acetaminophen overdoses.

Cumberland, based in Nashville, contends Allegan, Michigan-based Perrigo and InnoPharma of Piscataway, New Jersey, are planning to introduce copies of the drug before the patent-protection expires in 2026.

“Such conduct will constitute infringement” and create “a reasonable apprehension of irreparable harm” to Cumberland, its lawyers said in two complaints filed yesterday in Delaware federal court in Wilmington.

Acetadote is used in hospital emergency rooms to limit liver damage from life-threatening overuse of the pain reliever acetaminophen -- a leading cause of poisoning in the U.S. -- according to Cumberland.

H. Rajan Sharma, InnoPharma general counsel, said the company had no comment on the lawsuit. Arthur Shannon, a Perrigo spokesman, didn’t immediately return phone and e-mail messages seeking comment.

The cases are Cumberland v. Perrigo, 12cv619, and Cumberland v. InnoPharma, 12cv618, U.S. District Court, District of Delaware (Wilmington).

To see the patent, click: 8,148,356.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.